Stay informed on developments in cancer and oncology diagnosis, prevention and treatment through these curated webinars. As the race toward a cure for cancer continues, advances in cancer research are constantly revealed as innovation in the field of oncology progresses.
High-throughput screening is widely useful in identifying genes and pathways that drive changes in cell behavior such as cell cycle regulation, metastasis, and drug resistance. Millipor...
Natural killer cells (NKs) are lymphocytes of the innate immune system that target and kill cancer cells through the secretion of lytic granules containing granzyme B and perforin. This proce...
The detection of circulating molecular biomarkers is useful for monitoring pathogenic processes and response to therapeutic intervention1,2. In cancer, genomic and proteomic biomarkers are us...
Multiplex detection of oncogenic mutations using LNA-based assays on the QIAcuity digital PCR system Digital PCR (dPCR) enables specific and sensitive detection of genetic alterations in onc...
Tumor mutational burden (TMB) is an emerging biomarker that correlates with response to immunotherapeutic agents, such as checkpoint inhibitors. Recent studies indicate that a high mutation l...
Osteosarcoma (OS) is the most common bone tumor in pediatric and adolescent/young adult patients. Over the past three decades, significant improvements in the survival rates or therapeutic ap...
RNA sequencing unlocks the mysteries hidden in the transcriptome. Whether your goal is gene expression analysis, gene fusion analysis, SNP analysis or miRNA expression analysis, achieving hig...
In order to expand the treatment options of cancers driven by oncogenic RAS, new cell surface targets need to be identified and characterized. Here, we describe mass spectrometry based phenot...
Join this year's poster presenters in the Poster Hall during the Poster Networking Hour, Wednesday, September 20th, from 10:00 AM –11:00 AM PDT , to chat live about their posters a...
While circulating cell-free DNA (ccfDNA) and to some extend CTCs from blood are routinely used as analyte in liquid biopsy cancer research applications, circulating cell-free RNA (ccfRNA) ha...
The quest to cure cancer through the manipulation the immune system has been at the forefront of science for the past half-decade. The result has been the emergence of a multitude of promisin...
Understanding the immune repertoire is an important aspect of immuno-oncology research, which can be used to gather insights into the function and overall status of the immune system. We have...
Genomic data is vast and increasingly sparse. This problem grows as we sequence more and more patients. Herein, Professor Ennis will describe an algorithmic tool that reduces the sparsity of...
Acral lentiginous melanoma (ALM) is a rare sun-shielded melanoma subtype associated with worse survival than cutaneous melanoma (CM), a more common form of skin cancer linked to exposure to u...
Lung cancer is the leading cause of cancer-related mortality worldwide. Large-scale sequencing studies have revealed the complex genomic landscape of NSCLC and genomic differences between lun...
Molecular analyses of cancer biology have tended to segregate between a focus on nucleic acids – DNA, RNA and their modifications – and a focus on proteins and protein function. P...
Immunotherapy: An unprecedented opportunity-Long-lasting/curative treatments-Lower side effects-Wide applicability-Natural mechanism of action-Locally produced T cell therapies&...
A hypoxic tumour microenvironment is a feature of solid tumours. Many tumour types contain high fractions of hypoxic tissue. The relationship between high levels of tumour hypoxia and a poor...
Two projects looking at novel approaches to targeting inflammatory breast cancer will be presented. Inflammatory breast cancer (IBC) is a unique, understudied, and most lethal subtype account...
The oncogenic transcription factor c-MYC (MYC) is deregulated, and often overexpressed, in more than 50% of cancers. MYC deregulation is associated with poor prognosis and aggressive disease,...
Nanopore sequencing has enormous potential for application to cancer, but specifically offers advantages into two main arenas, epigenetics and structural variation. Methylation is well-known...
Individuals of under-represented minority ancestry are at disproportional risk for higher incidence and mortality rates for particular cancers. The unequal burden of cancer in certain racial...
Background: Growing evidence supports the critical role of preexisting immune response in triple negative breast cancer (TNBC). However, there are limitations with current evaluation approac...
The deposition and removal of DNA and histone modifications depends on the availability of specific metabolites, suggesting that cellular metabolic pathways may dynamically regulate chromatin...
Pancreatic ductal adenocarcinoma (PDAC) has a five-year survival rate of only 9%. Acquired drug resistance is a major factor that limits the effectiveness of chemotherapy. Exosomes, secreted...
Recent advances in flow and mass cytometry have greatly expanded the number of immune cell parameters that can be interrogated, resulting in an improved understanding of the immune system het...
The detection of CTCs has been used as useful biomarkers in prognosis and monitoring therapeutic response of patients with metastatic cancer. However, during the course of cancer therapy, CTC...
High-throughput screening is widely useful in identifying genes and pathways that drive changes in cell behavior such as cell cycle regulation, metastasis, and drug resistance. Millipor...
